Company Handa Pharmaceuticals, Inc.

6620

TW0006620008

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Company contact information

Sector

Ratings for Handa Pharmaceuticals, Inc.

EPS Revisions

Annual profits - Rate of surprise

Sector Generic Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 03:30:00 15/05/2024 am IST			5-day change	1st Jan Change
139.5 ^TWD	+1.82%		+3.72%	-23.98%

02/04	Handa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Handa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Handa Pharmaceuticals Inc is a Taiwan-based pharmaceutical company focused on the development of niche drug. The Company integrates its own pharmaceutical development platform with patent analysis, medicine and pharmaceuticals regulatory, and market planning to focus on the development of high barrier and patentable niche products, including 505(b)2 new drug development and high barrier/patentable generics development. Its products include marketed products, such as Quetiapine XR Tablets for treatment of sleep disorder diseases, Lamotrigine XR Tablets for treatment of anti-epileptic diseases and Dexlansoprazole DR Capsules for treatment of erosive reflux esophagitis and non-erosive gastroesophageal reflux diseases. The Company's products are mainly sold to the United States, Canada and India.

TWD in Million	2022	Weight	2023	Weight	Delta
Generic Drugs 100.0 %	198	100.0 %	1,106	100.0 %	+459.66%

TWD in Million	2022	Weight	2023	Weight	Delta
Taiwan 100.0 %	198	100.0 %	1,106	100.0 %	+459.66%

Managers	Title	Age	Since
Fang Yue Liu CEO	Chief Executive Officer	-	01/05/01
Hsin Yue Chen DFI	Director of Finance/CFO	-	-
Mei Fang Chang BRD	Director/Board Member	-	08/16/08
Chun Liang Chen BRD	Director/Board Member	-	28/19/28
Li Qiao LAW	General Counsel	-	-
Chi Yue Yang AUD	Comptroller/Controller/Auditor	-	-
Stephen Douglas Cary PRN	Corporate Officer/Principal	-	-
Kuo Chun Sung PRN	Corporate Officer/Principal	-	22/14/22

Members of the board	Title	Age	Since
Chun Liang Chen BRD	Director/Board Member	-	28/19/28
Kuei Ching Wang BRD	Director/Board Member	-	28/17/28
Wei Li Lin BRD	Director/Board Member	-	28/17/28
Hsin Fang Wu BRD	Director/Board Member	-	31/16/31
Fang Yue Liu CEO	Chief Executive Officer	-	01/05/01
Kuo Chun Sung PRN	Corporate Officer/Principal	-	22/14/22
Mei Fang Chang BRD	Director/Board Member	-	08/16/08
Stephen Douglas Cary PRN	Corporate Officer/Principal	-	-
Chin Wu BRD	Director/Board Member	-	28/17/28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	141,088,000	141,088,000 ( 100.00 %)	0	100.00 %

Handa Pharmaceuticals, Inc.

Southern Taiwan Science Park No. 23 Nanke 3rd Road

741 47, Tainan

http://www.handapharma.com

address Handa Pharmaceuticals, Inc.(6620)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

139.5 TWD

Average target price

200 TWD

Spread / Average Target

+43.37%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Generic Pharmaceuticals

	1st Jan change	Capi.
HANDA PHARMACEUTICALS, INC.	-23.98%	597M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.28%	44.4B
OTSUKA HOLDINGS CO., LTD.	+24.60%	23.03B
SANDOZ GROUP AG	+19.22%	15.14B
CIPLA LIMITED	+12.87%	13.12B
ZYDUS LIFESCIENCES LIMITED	+44.67%	11.85B
ONO PHARMACEUTICAL CO., LTD.	-8.33%	6.99B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.07%	5.52B

Generic Pharmaceuticals